Prox­y­gen and Mer­ck strike li­cense deal worth up to $2.55B for pro­tein degra­da­tion

The buzzy pro­tein degra­da­tion field is get­ting an­oth­er mol­e­c­u­lar glue tie-up, stick­ing the Vi­en­na biotech Prox­y­gen with Mer­ck in a mul­ti-year part­ner­ship that could be …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER